Why the study?
Inflammation contributes significantly to HF development and progression, making specific anti-inflammatory treatment a novel approach to prevent and slow disease progression.
Do specific anti-inflammatory treatments targeting inflammatory mediators prevent or slow heart failure progression?
Do specific anti-inflammatory treatments targeting inflammatory mediators prevent or slow heart failure progression?
Targeting specific inflammatory mediators represents a novel therapeutic approach to prevent and slow the progression of heart failure.
Answers are grounded in this paper and cite their sources.
Chronic inflammation drives HF via immune-mitochondrial pathways; extends mechanistic understanding but leaves targeted therapies unproven.
Inflammation has emerged as an important contributor to heart failure (HF) development and progression. Current research data highlight the diversity of immune cells, proteins, and signaling pathways involved in the pathogenesis and perpetuation of heart failure. Chronic inflammation is a major cardiovascular risk factor. Proinflammatory signaling molecules in HF initiate vicious cycles altering mitochondrial function and perturbing calcium homeostasis, therefore affecting myocardial contractility. Specific anti-inflammatory treatment represents a novel approach to prevent and slow HF progression. This review provides an update on the putative roles of inflammatory mediators involved in heart failure (tumor necrosis factor-alpha; interleukin 1, 6, 17, 18, 33) and currently available biological and non-biological therapy options targeting the aforementioned mediators and signaling pathways. We also highlight new treatment approaches based on the latest clinical and experimental research.
No takes yet. Share an insight, caveat, or question.
Szabo et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: